FDA warns about fake Ozempic in U.S. supply chain

The FDA on Monday urged patients and doctors to check that their Ozempic prescriptions are legitimate after the agency seized several hundred fake units of the diabetes drug.

The Food and Drug Administration on Monday urged patients and doctors to check that their Ozempic prescriptions are legitimate after the agency seized several hundred units of fake versions of the diabetes drug in the U.S.

Novo Nordisk, the maker of Ozempic and the weight loss drug Wegovy, told the FDA on April 3 that counterfeit 1-milligram injections were being distributed outside its authorized supply chain in the U.S., the agency said in a news release. That means it likely entered the market through unofficial means, like unauthorized distributors or resellers.

The FDA said it seized the counterfeit products — labeled with lot number PAR0362 and serial numbers starting with the first eight digits 51746517 — on April 9.

FDA was notified by Novo Nordisk on April 3 that several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg were in the U.S. drug supply chain.FDAThe agency said it’s aware of six adverse event reports linked to the lot — however, none of them appear to be associated with the counterfeit product. The agency and Novo Nordisk are testing the fake products to identify whether they’re safe. Genuine Ozempic can come with side effects, including stomach problems, so it's not clear whether the adverse events were caused by typical use.

The fake versions underscore the soaring popularity and demand for the diabetes drug Ozempic, which is often used “off label” for weight loss, as well as similar GLP-1 drugs.

https://www.nbcnews.com/health/health-news/fda-warns-fake-ozempic-us-supply-chain-rcna201184

---